Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics, Inc.

Arcutis (Nasdaq: ARQT) was founded in 2016 to address significant unmet needs in medical dermatology. The company is an early commercial stage biopharmaceutical company focused on developing and commercializing best-in-class products.

Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat dermatological diseases and disorders. 

Our management team has extensive expertise in the development and commercialization of medical dermatology products, having held key leadership roles at a number of leading dermatology companies and, collectively, has successfully developed more than 50 FDA-approved products. We believe that by leveraging our team’s unique experience and demonstrated expertise to identify, develop and commercialize best-in-class molecules against validated targets, we will be able to develop differentiated products in less time, at lower cost, and at substantially lower risk than other approaches.

Arcutis'​ combination of vision, unmet medical need, experienced management and strategic approach has attracted support from leading investors in the life sciences sector.

SLR Capital Partners

Vivo Capital

Omega Funds

OrbiMed

Pivotal bioVenture Partners

RA Capital Management

Goldman Sachs

Bain Capital

BlackRock

Frazier Healthcare Partners

HBM Healthcare Investments AG

Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT)

For #BlackHistoryMonth, we’re celebrating the legacies of Black dermatologists who paved the way in studying #skindisease in people of color. Learn about Dr. John A. Kenney, Jr., known as “the dean of Black dermatology” below. #skinofcolor

#Plaquepsoriasis is a serious #skindisease that can impact far more than your skin. Check out some common symptoms of plaque psoriasis below and find more resources from National Psoriasis Foundation at https://bit.ly/3uEnxib

#NEWS: Today, we announced that the Journal of the American Academy of Dermatology published positive results from the pivotal Phase 3 STRATUM #clinicaltrial evaluating our topical, steroid-free treatment for #seborrheicdermatitis. 

Learn more: https://bit.ly/47Tbvza 


#NEWS: Today, we announced the nationwide availability of our topical, steroid-free foam for the treatment of adults and children ages 9+ with #seborrheicdermatitis. Learn more: https://ow.ly/8azH50Qt4XA

At the annual Maui Derm meeting, we’ll share a look at our ongoing work in #atopicdermatitis. Learn more about our posters below.

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	537K -	1.80M 235.38%	1.41M 21.99%	7.14M 408.19%	7.35M 2.98%	8.83M 20.05%	11.99M 35.86%
accumulated other comprehensive income loss			-1K -	-2K 100%	-255K 12,650%	-1.09M 325.88%	4K 100.37%
cash and cash equivalents	3.42M -	39.39M 1,052.55%	63.34M 60.78%	65.08M 2.76%	96.45M 48.20%	53.64M 44.38%	89.32M 66.52%
cash and short term investments	3.42M -	50.94M 1,390.35%	101.27M 98.79%	284.44M 180.89%	387.06M 36.08%	409.59M 5.82%	272.79M 33.40%
common stock				4K -	5K 25%	6K 20%	9K 50%
deferred revenue
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets						7.19M -	6.44M 10.43%
intangible assets						7.19M -	6.44M 10.43%
inventory				-510K -	1.18M 331.37%	7.51M 536.78%	13.13M 74.79%
long term debt			129K -	4.96M 3,748.06%	77.12M 1,453.67%	201.89M 161.77%	201.80M 0.04%
long term investments
net debt	-3.42M -	-39.39M 1,052.55%	-63.03M 60.00%	-60.12M 4.62%	-18.89M 68.58%	148.90M 888.17%	116.59M 21.70%
net receivables				510K -	362K 29.02%	8.46M 2,236.46%	25.81M 205.12%
other assets
other current assets	401K -	158K 60.60%	5.21M 3,196.84%	8.38M 60.97%	14.17M 69.02%	10.61M 25.13%	18.70M 76.27%
other current liabilities	155K -	872K 462.58%	3.65M 319.04%	15.46M 323.15%	25.54M 65.18%	28.32M 10.90%	33.94M 19.84%
other liabilities
other non current assets			47K -	78K 65.96%	78K 0%	78K 0%	596K 664.10%
other non current liabilities	8.12M -	72.41M 791.77%	166.68M 130.18%	82K 99.95%	25K 69.51%		4.23M -
othertotal stockholders equity	28K -	289K 932.14%	-165.25M 57,278.89%	174.30M 205.48%	706.23M 305.18%	930.42M 31.74%	1.07B 15.06%
preferred stock			166.49M -	298.27M 79.15%
property plant equipment net			491K -	5.37M 992.67%	5.30M 1.19%	4.60M 13.19%	3.90M 15.25%
retained earnings	-5.02M -	-24.28M 383.49%	-66.27M 172.99%	-201.95M 204.73%	-408.31M 102.18%	-719.76M 76.28%	-981.90M 36.42%
short term debt			178K -		433K -	657K 51.73%	735K 11.87%
short term investments		11.55M -	37.93M 228.50%	219.36M 478.34%	290.61M 32.48%	355.95M 22.48%	183.46M 48.46%
tax assets
tax payables
total assets	3.82M -	51.10M 1,237.99%	107.01M 109.43%	298.27M 178.72%	408.15M 36.84%	449.27M 10.08%	341.37M 24.02%
total current assets	3.82M -	51.10M 1,237.99%	106.47M 108.37%	292.83M 175.02%	402.77M 37.55%	437.41M 8.60%	330.43M 24.46%
total current liabilities	692K -	2.67M 286.27%	5.24M 95.92%	22.60M 331.58%	33.33M 47.45%	37.81M 13.45%	46.67M 23.44%
total debt			307K -	4.96M 1,516.94%	77.56M 1,462.39%	202.54M 161.15%	205.92M 1.67%
total investments		11.55M -	37.93M 228.50%	219.36M 478.34%	290.61M 32.48%	355.95M 22.48%	183.46M 48.46%
total liabilities	8.81M -	75.08M 752.08%	172.04M 129.13%	27.65M 83.93%	110.47M 299.58%	239.69M 116.97%	252.70M 5.43%
total liabilities and stockholders equity	3.82M -	51.10M 1,237.99%	107.01M 109.43%	298.27M 178.72%	408.15M 36.84%	449.27M 10.08%	341.37M 24.02%
total non current assets			538K -	5.44M 911.71%	5.38M 1.18%	11.87M 120.64%	10.93M 7.87%
total non current liabilities	8.12M -	72.41M 791.77%	166.80M 130.35%	5.05M 96.97%	77.15M 1,428.91%	201.89M 161.68%	206.03M 2.05%
total stockholders equity	-4.99M -	-23.99M 380.41%	-65.03M 171.10%	270.62M 516.15%	297.68M 10.00%	209.58M 29.59%	88.67M 57.69%

NASDAQ:ARQT

Arcutis Biotherapeutics, Inc.

Last Close

10.10

26/07 20:00

Market Cap

1.14B

Beta: 0.45

Volume Today

1.46M

Avg: 993.92K

PE Ratio

−1.36

PFCF: −2.77

Preview